LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Kodu・Aktsiate loetelu・MacroGenics Inc
Search

MacroGenics Inc

Suletud

SektorTervishoid

3.88 -0.51

Osta

Hinna uuendus 10. juuni 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.82

Max

4.03

Põhinäitajad

By Trading Economics

Sissetulek

-23M

-37M

Müük

-20M

21M

Aktsiakasum

-0.58

Kasumimarginaal

-177.011

Töötajad

293

EBITDA

-17M

-32M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+63.57% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

12. aug 2026

Turustatistika

By TradingEconomics

Turukapital

59M

247M

Eelmine avamishind

4.39

Eelmine sulgemishind

3.88

Uudiste sentiment

By Acuity

50%

50%

154 / 344 Pingereas Healthcare

MacroGenics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. juuni 2026, 23:36 UTC

Tulu

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Loe

10. juuni 2026, 23:19 UTC

Kuumad aktsiad

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Loe

10. juuni 2026, 23:09 UTC

Suurimad hinnamuutused turgudel

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Loe

10. juuni 2026, 23:04 UTC

Tulu

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Loe

10. juuni 2026, 20:44 UTC

Suurimad hinnamuutused turgudel

Caterpillar Raises Quarterly Dividend 8%

DJ

Loe

10. juuni 2026, 23:49 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Northern Star Should Take No Options Off The Table

DJ

Loe

10. juuni 2026, 23:48 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Loe

10. juuni 2026, 23:48 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Loe

10. juuni 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Loe

10. juuni 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Loe

10. juuni 2026, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Loe

10. juuni 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

10. juuni 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

10. juuni 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Loe

10. juuni 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Loe

10. juuni 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Loe

10. juuni 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Loe

10. juuni 2026, 21:57 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 21:52 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 21:35 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 21:22 UTC

Tulu

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:39 UTC

Market Talk
Tulu

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Loe

10. juuni 2026, 20:34 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 20:33 UTC

Tulu

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Loe

10. juuni 2026, 20:33 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:33 UTC

Market Talk
Tulu

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

MacroGenics Inc Prognoos

Hinnasiht

By TipRanks

63.57% tõus

12 kuu keskmine prognoos

Keskmine 6.33 USD  63.57%

Kõrge 9 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi MacroGenics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

2

Osta

2

Hoia

0

Müü

Põhineb 4 analüütiku instrumendi MacroGenics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

154 / 344 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat